본문 바로가기

EU · EudraLex Vol.4

EU GMP Part I, Chapter 7

Outsourced Activities

Status of the document: revision 1

조항 목차

  1. PrinciplePrinciple
  2. 7.1There should be a written Contract covering the outsourced activities, the products or operations to which they are related, and any techni…
  3. 7.2All arrangements for the outsourced activities including any proposed changes in technical or other arrangements should be in accordance wi…
  4. 7.3Where the marketing authorization holder and the manufacturer are not the same, appropriate arrangements should be in place, taking into ac…
  5. 7.4The pharmaceutical quality system of the Contract Giver should include the control and review of any outsourced activities. The Contract Gi…
  6. 7.5Prior to outsourcing activities, the Contract Giver is responsible for assessing the legality, suitability and the competence of the Contra…
  7. 7.6The Contract Giver should provide the Contract Acceptor with all the information and knowledge necessary to carry out the contracted operat…
  8. 7.7The Contract Giver should monitor and review the performance of the Contract Acceptor and the identification and implementation of any need…
  9. 7.8The Contract Giver should be responsible for reviewing and assessing the records and the results related to the outsourced activities. He s…
  10. 7.9The Contract Acceptor must be able to carry out satisfactorily the work ordered by the Contract Giver such as having adequate premises, equ…
  11. 7.10The Contract Acceptor should ensure that all products, materials and knowledge delivered to him are suitable for their intended purpose.
  12. 7.11The Contract Acceptor should not subcontract to a third party any of the work entrusted to him under the Contract without the Contract Give…
  13. 7.12The Contract Acceptor should not make unauthorized changes, outside the terms of the Contract, which may adversely affect the quality of th…
  14. 7.13The Contract Acceptor should understand that outsourced activities, including contract analysis, may be subject to inspection by the compet…
  15. 7.14A Contract should be drawn up between the Contract Giver and the Contract Acceptor which specifies their respective responsibilities and co…
  16. 7.15The Contract should describe clearly who undertakes each step of the outsourced activity, e.g. knowledge management, technology transfer, s…
  17. 7.16All records related to the outsourced activities, e.g. manufacturing, analytical and distribution records, and reference samples, should be…
  18. 7.17The Contract should permit the Contract Giver to audit outsourced activities, performed by the Contract Acceptor or his mutually agreed sub…
표지·목차 원문

Ref. Ares(2012)778531 - 28/06/2012

EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL

Health Systems and Products Medicinal Products - Quality, safety and efficacy

Brussels, SANCO/AM/sl/ddg1.d.6(2012)860362

EudraLex

The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use

Chapter 7 Outsourced Activities

Legal basis for publishing the detailed guidelines: Article 47 of Directive 2001/83/EC on the Community code relating to medicinal products for human use and Article 51 of Directive 2001/82/EC on the Community code relating to veterinary medicinal products. This document provides guidance for the interpretation of the principles and guidelines of good manufacturing practice (GMP) for medicinal products as laid down in Directive 2003/94/EC for medicinal products for human use and Directive 91/412/EEC for veterinary use.

Status of the document: revision 1

Reasons for changes: In view of the ICH Q10 guideline on the Pharmaceutical Quality System, Chapter 7 of the GMP Guide has been revised in order to provide updated guidance on outsourced GMP regulated activities beyond the current scope of contract manufacture and analysis operations. The title of the Chapter has been changed to reflect this.

Deadline for coming into operation: 31 January 2013 Commission Européenne, B-1049 Bruxelles / Europese Commissie, B-1049 Brussel – Belgium. Telephone: (32-2) 299 11 11

출처: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · 수집일 2026-11-15

Weekly Newsletter

이런 지적, 매주 월요일 한국어로 받아보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

매주 월요일 발송 · 구독 신청 시 확인 메일이 발송됩니다 · 수신거부는 모든 메일 하단에서 가능합니다.